Gelesis is a biotechnology company developing therapies for weight loss and gastrointestinal-related diseases. It develops a hydrogel platform technology to treat obesity and other chronic diseases related to the GI tract. The portfolio of the company includes a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes, and chronic idiopathic constipation.